{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:08:20Z","timestamp":1791281300248,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jval.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T02:51:40Z","timestamp":1364179900000},"page":"345-355","source":"Crossref","is-referenced-by-count":89,"title":["Understanding the Costs of Care for Cystic Fibrosis: An Analysis by Age and Health State"],"prefix":"10.1016","volume":"16","author":[{"given":"Kees","family":"van Gool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Delatycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Massie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2012.12.003_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","article-title":"Cystic fibrosis","author":"Welsh","year":"2001"},{"key":"10.1016\/j.jval.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.healun.2009.08.004","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009","volume":"28","author":"Christie","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jval.2012.12.003_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.healun.2009.08.002","article-title":"Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart\/Lung Transplantation Report-2009","volume":"28","author":"Aurora","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jval.2012.12.003_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2165\/00019053-200321140-00002","article-title":"Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies","volume":"21","author":"Krauth","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/thx.47.9.684","article-title":"A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients","volume":"47","author":"Robson","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.jval.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/thx.51.3.298","article-title":"Cost of care of patients with cystic fibrosis in the Netherlands in 1990-1","volume":"51","author":"Wildhagen","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.jval.2012.12.003_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1542\/peds.100.2.197","article-title":"Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid program, fiscal year 1993","volume":"100","author":"Ireys","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2012.12.003_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1569-1993(03)00024-9","article-title":"Cost of care and clinical condition in paediatric cystic fibrosis patients","volume":"2","author":"Baumann","year":"2003","journal-title":"J Cys Fibros"},{"key":"10.1016\/j.jval.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.19.15.1159.30580","article-title":"Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human dnase","volume":"19","author":"Johnson","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jval.2012.12.003_bib10","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1542\/peds.103.6.e72","article-title":"The cost of medical care for patients with cystic fibrosis in a health maintenance organization","volume":"103","author":"Lieu","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/11588870-000000000-00000","article-title":"Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre","volume":"30","author":"Heimeshoff","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1017\/S0266462306051476","article-title":"Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France","volume":"22","author":"Horvais","year":"2006","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2012.12.003_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/11313980-000000000-00000","article-title":"Outpatient medication costs of patients with cystic fibrosis in Germany","volume":"8","author":"Eidt-Koch","year":"2010","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jval.2011.11.027","article-title":"Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial","volume":"15","author":"DeWitt","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.12.003_bib15","unstructured":"Cystic Fibrosis Australia. Australian Cystic Fibrosis Data Registry Information Management Policy and Practices. Sydney: Cystic Fibrosis Australia, 2005."},{"key":"10.1016\/j.jval.2012.12.003_bib16","unstructured":"Cystic Fibrosis Australia. Cystic Fibrosis in Australia 2007: 10th Annual Report from the Australian Cystic Fibrosis Data Registry. Sydney: Cystic Fibrosis Australia, 2009."},{"key":"10.1016\/j.jval.2012.12.003_bib17","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Panel on Genetic Testing for Cystic Fibrosis. Genetic testing for cystic fibrosis [National Institutes of Health Consensus Development Conference on Genetic Testing for Cystic Fibrosis]. Arch Intern Med 1999;159:1529\u201339.","DOI":"10.1001\/archinte.159.14.1529"},{"key":"10.1016\/j.jval.2012.12.003_bib18","doi-asserted-by":"crossref","unstructured":"Anyanwu AC, McGuire A, Rogers CA, et al. An economic evaluation of lung transplantation. J Thorac Cardiovasc Surg 2002;123:411\u2013418; discussion 18\u201320.","DOI":"10.1067\/mtc.2002.120342"},{"key":"10.1016\/j.jval.2012.12.003_bib19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/0272989X09340585","article-title":"The half-cycle correction: banish rather than explain it","volume":"29","author":"Barendregt","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2012.12.003_bib20","unstructured":"DOHA. Manual of Resource Items and Their Associated Costs for Use in Submissions to the Pharmaceutical Benefits Advisory Committee Involving Economic Evaluation. Canberra: Australian Department of Health and Ageing, 2002."},{"key":"10.1016\/j.jval.2012.12.003_bib21","unstructured":"DOHA. National Hospital Cost Data Collection Cost Report. Canberra: Australian Department of Health and Ageing, 2009."},{"key":"10.1016\/j.jval.2012.12.003_bib22","unstructured":"DOHA. Pharmaceutical Benefits Schedule. Canberra: Australian Department of Health and Ageing, 2009."},{"key":"10.1016\/j.jval.2012.12.003_bib23","unstructured":"DOHA. Medicare Benefits Schedule: Operating from 1 November 2009. Canberra: Australian Department of Health and Ageing, 2009."},{"key":"10.1016\/j.jval.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5694\/j.1326-5377.2009.tb03308.x","article-title":"Variability in the rate of prescription and cost of domiciliary oxygen therapy in Australia","volume":"191","author":"Serginson","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.jval.2012.12.003_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0163-4453(03)00135-X","article-title":"A randomised trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases","volume":"48","author":"Wolter","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.jval.2012.12.003_bib26","unstructured":"Cystic Fibrosis NSW. Online store. 2010;2010."},{"key":"10.1016\/j.jval.2012.12.003_bib27","unstructured":"Government of Western Australia. Price Schedule \u2013 WA Government. Perth: Department of Treasury and Finance, 2007."},{"key":"10.1016\/j.jval.2012.12.003_bib28","unstructured":"PBAC. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Department of Health and Ageing, 2008."},{"key":"10.1016\/j.jval.2012.12.003_bib29","unstructured":"ABS. 6401.0 \u2013 Consumer Price Index, Australia. Canberra: Australian Bureau of Statistics, 2010."},{"key":"10.1016\/j.jval.2012.12.003_bib30","series-title":"Clinical Care Enhancements for the Australian Cystic Fibrosis Data Registry","author":"Stewart","year":"2009"},{"key":"10.1016\/j.jval.2012.12.003_bib31","unstructured":"Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2009. Bethesda, MD: Cystic Fibrosis Foundation, 2011."},{"key":"10.1016\/j.jval.2012.12.003_bib32","series-title":"Cost of Care for Individuals with Cystic Fibrosis in Alberta: A Regression Approach to Determining Important Cost Drivers","author":"Johnson","year":"1996"},{"key":"10.1016\/j.jval.2012.12.003_bib33","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMe1110323","article-title":"Therapy for cystic fibrosis: the end of the beginning?","volume":"365","author":"Davis","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.12.003_bib34","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the g551d mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512042684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512042684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T08:48:56Z","timestamp":1595580536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301512042684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1098301512042684"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2012.12.003","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}